Wednesday, 22 January 2014

Global Parkinson's Disease Market 2012-2016



TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinsons Disease market has also been witnessing the transition toward using drugs that have new mechanisms of action. However, weak pipeline landscape could pose a challenge to the growth of this market.

TechNavio's report, the Global Parkinson's Disease Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Parkinson's Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include GlaxoSmithKline plc, Novartis AG, Orion Corp., and Teva Pharmaceuticals Industries Ltd.

The other vendors mentioned in the report are AbbVie Inc., Acadia Pharmaceuticals Inc., Avicena Group Inc., BoehringerIngelheim GmbH, Impax Laboratories Inc., Lundbeck A/S, Newron Pharmaceuticals SpA, Solvay Pharmaceuticals Inc., and Valeant International SRL.


Key questions answered in this report:

* What will the market size be in 2016 and what will be the growth rate?
* What are key market trends?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
* What are the market opportunities and threats faced by key vendors?
* What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details provided within the report.

To order this report:


Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE:  Researchonglobalmarkets.com

RELATED VIDEO:



No comments:

Post a Comment